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Abstract: The purpose in this study was to investigate poly(ethylene glycol)-modified poly 
(d,l-lactide-co-glycolide) nanoparticles (PLGA-PEG-NPs) loading 9-nitrocamptothecin (9-NC) 
as a potent anticancer drug. 9-NC is an analog of the natural plant alkaloid camptothecin that 
has shown high antitumor activity and is currently in the end stage of clinical trial. Unfortu-
nately, at physiological pH, these potent agents undergo a rapid and reversible hydrolysis with 
the loss of antitumor activity. Previous researchers have shown that the encapsulation of this 
drug in PLGA nanoparticles could increase its stability and release profile. In this research we 
investigated PLGA-PEG nanoparticles and their effect on in vitro characteristics of this labile 
drug. 9-NC-PLGA-PEG nanoparticles with particle size within the range of 148.5 ± 30 nm were 
prepared by a nanoprecipitation method. The influence of four different independent variables 
(amount of polymer, percent of emulsifier, internal phase volume, and external phase volume) 
on nanoparticle drug-loading was studied. Differential scanning calorimetry and X-ray diffrac-
tometry were also evaluated for physical characterizing. The results of optimized formulation 
showed a narrow size distribution, suitable zeta potential (+1.84), and a drug loading of more 
than 45%. The in vitro drug release from PLGA-PEG NPs showed a sustained release pattern 
of up to 120 hours and comparing with PLGA-NPs had a significant decrease in initial burst 
effect. These experimental results indicate that PLGA-PEG-NPs (versus PLGA-NPs) have a 
better physicochemical characterization and can be developed as a drug carrier in order to treat 
different malignancies.
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Camptothecin (CPT) and its derivatives play an important role in the treatment of differ-
ent malignancies.1,2 They all have a unique mechanism of action, targeting the nuclear 
enzyme of DNA topoisomerase I (topo I). CPT inhibits this enzyme by blocking the 
rejoining step of the cleavage/relegation reaction of topo I, resulting in accumulation 
of a covalent reaction intermediate, the cleavage complex. The primary mechanism 
of cell killing by CPT is S-specific killing through potentially lethal collision between 
advancing replication forks and topo-I cleavable complexes.3,4,5 In the structure of these 
analogues, common features include an aromatic 5-ring system and a lactone moiety 
which is crucial for their antitumor activity.4
9-Nitrocamptothecin (9-NC) is a novel, lipophilic derivative of CPT which has a 
high antitumor activity which has been used in several clinical trial studies in order 
to treat advanced pancreatic carcinoma, ovarian epithelial cancer and leukemia.2 
Unfortunately, the lactone form depends on the pH of the medium and easily inverts to 
carboxylate form in alkaline pHs, especially when exposed to serum albumin proteins, 
which remove its antitumor properties (see Figure 1).4,6International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Because of instability at biological pH and low water 
solubility, the delivery of lipophilic derivatives like 9-NC 
is quite challenging.7 To eradicate these problems, drug 
delivery systems such as liposomes, nanocapsules, micellar 
systems, and conjugates have been used to overcome the 
cellular resistance and take active pharmacologic agents to 
the target tissue, increasing bioavailability and drug affect 
in target tissue, solubilizing for intravascular delivery, and 
improving the stability of therapeutic agents for pH hydro-
lysis and enzymatic degradation.8,9
Polymeric nanoparticles composed of PLGA as a 
biocompatible and biodegradable compound have more 
stability and lower toxicity compared to other drug delivery 
systems like solid lipid nanoparticles (SLNs).7 But since 
these structures can be easily opsonized by the mononuclear 
phagocytic system (MPS) due to their lipophilic surface, 
they have a short half-life with an in vivo failed function. To 
address this burden, some hydrophilic conjugates are used 
to prepare the solution, which have a hydrophilic surface 
with a lipophilic core in the center called the nanoparticle 
core shell effect.10–14
The most common formulations applied in these polymers 
are composed of PEG structures named copolymers; the 
purpose of these PEG chains is to create a barrier layer to 
block the adhesion of opsonins present in the blood serum, 
so that the particles can remain camouflaged or invisible to 
phagocytic cells.15,16
PEGylation simply refers to the decoration of a particle 
surface by covalently grafting, entrapping, or adsorbing 
PEG chains. Also, in the case of biodegradable nanopar-
ticles, PEG chains can be incorporated as copolymers 
throughout the particle so that some surface PEG chains 
are always available even after the degradation of surface 
layers.15–17
Other important points in the application of these copoly-
mers are controlled initial release and smaller size compared 
to nanoparticles containing PLGA polymers which leads to 
increased in vivo stability and effect.17–22
Copolymeric nanoparticles have different characteristics 
in that the formation of each of them depends on the copo-
lymer composition, molecular geometry, the length of the 
chain, and the method of preparation.23–26
The aim in present study was to prepare 9-NC loaded 
nanoparticles by PLGA-PEG copolymer and compare the 
physicochemical properties results with a previous study 
which involved the use of PLGA polymer.7 The resulting 
9-NC nanoparticles were characterized with regard to mor-
phology, size, drug loading, and in vitro drug release.
Materials and methods
Materials
9-Nitrocamptothecin (9-NC), 99.8% pure, was purchased 
from Yuanjian Pharmaceutical Technology Develop Co., 
(China). Poly(d, l-lactide-  co-glycolide) (PLGA; 50:50 Mw 
12000, inherent viscosity of 0.16–0.24 dl/g) and PLGA-PEG 
5% (Mw 12000) were obtained from Bohringer Ingelheim 
Co. (Germany). Polyvinyl alcohol (PVA; Mw 30,000 Da, 87% 
hydrolyzed) was a gift from Mowiol (Germany). Analytical 
grade acetone and acetonitrile were obtained from Merck 
(Darmstadt, Germany). All other chemical reagents used 
were of   pharmaceutical grade.
Preparation of nanoparticles
The nanoprecipitation method was employed for the 
formation of drug-encapsulated PLGA-PEG nanopar-
ticles similarly to previously performed study.7 Briefly, 
PLGA-PEG was dissolved in acetone. Then the copoly-
mer solution containing exact amount of drug was added 
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Figure 1 chemical structure of lactone and carboxylate forms of 9-nitrocamptothecin showing their equilibrium reaction, (A) lactone form, (B) carboxylate form.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
465
Long circulating 9-nitrocamptothecin nanoparticles
drop-wise (0.5 mL/min) into PVA aqueous solution (pH 
was adjusted to 3 by 0.1 N HCl) and stirred magneti-
cally at room temperature until complete evaporation of 
the organic solvent. Next, the nanoparticle suspension 
was centrifuged by ultracentrifuge   (XL-90 Beckman, 
Brea, CA) at 40,000 rpm and 4°C for 90 minutes. The 
separated nanoparticles were redispersed and centrifuged 
three times in distilled water (pH 3) in order to remove 
free drug and excess surfactant completely. The acidity of 
the medium used in this process was because of stabilizing 
the lactone form of 9-nitrocamptothecin. Finally, nano-
particles were dried via desiccator at room temperature 
for 24 hours, and then were characterized.
In this study, we evaluated the effects on drug loading of 
four different variable amounts of polymer, percent of emul-
sifier, internal phase volume, and external phase volume, to 
approach optimum formulation by one at a time statistical 
method.
characterization of 9-Nc
Determination of particle size
The mean size and zeta potential of nanoparticles were 
measured by photon correlation spectroscopy (PCS) 
(SEMATech), at a scattering angle of 90° and at a tem-
perature of 25°C using samples appropriately diluted with 
super pure water.
Particle morphology
The morphology of nanospheres was observed by scanning 
electron microscopy (SEM) (Philips, the Netherlands). 
Samples were coated with a thin layer of colloidal gold 
applied in a cathodic vacuum evaporator before observation 
by SEM at 20 KV .
Differential scanning calorimetry (Dsc)
The physical state of the nanoparticle components was 
characterized by thermal analysis in DSC-60 analyzer (Shi-
madzu Co., Kyoto, Japan). Samples (10 mg) were sealed 
into aluminum pans and heated in an inert atmosphere of 
nitrogen with a heat rate of 10°C/min. Calibration of the 
system was performed using octadecane and indium.
X-ray diffractometry 
An X-ray diffractometer, (XRD; Philips APD), was used 
for diffraction studies. The samples were exposed to CuKα 
radiation (40 kv, 20 mA) and scanned from 2° to 70°, 2θ 
at a step size of 0.02°, and step time of 5 S. Samples used 
for XRD analysis were exactly the same as those used for 
DSC analysis.
Determination of drug content
Drug content was determined using a validated high-pressure 
liquid chromatography (HPLC) method.7 Nanoparticles were 
dissolved in acetonitrile (2 mL) and sonicated for 2 minutes. 
The organic solvent was evaporated until the stream of nitro-
gen gas and then was dissolved in 1.5 mL mobile phase of 
HPLC assay.
The 1001 HPLC was equipped with an ultraviolet detec-
tor model 2700 at 370 nm (Knauer, Germany) and a column 
Figure 2 scanning table electron micrograph of 9-nitrocamptothecin nanoparticles.
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of Nucleosil-100 C18 with the mobile phase containing a 
mixture of acetonitrile-water (43:57, V/V , pH 3).
The amount of drug loading in nanoparticles was calcu-
lated using the following equation:
Encapsulation
 
efficiency (%) =
(Amount of 9-NC 
in nanopartic cles)
(Amount of 9-NC used 
in formulation)
×100
In vitro drug release
The in vitro drug release of nanoparticles was determined by 
dialysis method using Franz diffusion cell. A total of 2 mL of 
NP suspension in phosphate-buffered saline (PBS, 0.1M, pH 
7.4) was placed in donor site and 25 mL PBS in receptor part 
incubated at 37°C under magnetic stirring (200 rpm). At specific 
time intervals, 500 µL of medium was taken and replaced with 
the same volume of fresh PBS. The taken samples were acidified 
with 5% perchloric acid before UV analysis to evaluate the total 
form of 9-NC (lactone and carboxylate forms). The obtained 
release data were evaluated by zero order, first order and Higuchi 
equations to assay the release kinetics. To select the best model, 
the relevant correlation coefficients were considerable.
statistical analysis
The experiments were repeated three times and the results 
were expressed as mean ± standard deviation. Statisti-
cal analysis was undertaken using Student’s t test and 
P value , 0.05 were considered statistically significant.
Results and discussion
Carrier-mediated drug delivery offers a number of design 
opportunities to tailor a delivery route around the details 
of particular drugs, including their modes of action and 
potential side effects.27,28 Such carrier functions can be 
quite diverse, including transport to the targeted tissue, 
control of intracellular distribution, and protection against 
degradation or elimination by the mononuclear phagocytic 
systems (MPS).29,30 For instance, it has been demonstrated 
that Paclitaxel nanoparticles have a long time release 
accompanied with a small size which is so important for 
phagocytic systems.15,31–33 Also preparing NPs of tumor 
necrosis factor-α (TNF-α), cisplatin, indomethacin, 
iboprufen, and so many other drugs has shown that these 
carriers can deliver the drug to the tissue in the best way 
with the least side effects and a long time circulation in 
the body.22,34,35 All these features prompted us to investi-
gate the possibility of developing these nanoparticles as 
a controlled release drug formulation. In the development 
of new colloidal structures as circulating carriers, the 
assessment of their performance as drug carriers neces-
sarily comprises the knowledge of the loaded amount of 
drug, its physical state and distribution inside the carrier, 
as well as its release kinetics and the influence of envi-
ronmental factors on it.
In our previous study,7 PLGA-loaded 9-NC nanoparticles 
were prepared by nanoprecipitation method and four different 
independent variables on the characteristics of nanoparticles 
were evaluated. The results of optimized formulations showed 
a narrow size distribution with a polydispersity index of 0.01%, 
an average diameter of 207 ± 26 nm, and a drug loading of 
more than 30%. The in vitro drug release profile showed a sus-
tained 9-NC release up to 160 hours indicating the controlled 
release of 9-NC via nanoparticles.
But, since PLGA nanoparticles can be uptaken by 
phagocytic systems easily and have a rapid initial release 
(15%–20% in first 5 hours), in this study, we used PLGA-
PEG for preparing nanoparticles and characterized them 
Table 1 results of drug loadings according to amount of polymer (n = 3)
Formulation Polymer 
(mg)
PVA 
(mg)
Int. phase 
(mL)
Ext. phase 
(mL)
EE (%)
1 50  50 12 22 13.5 ± 3.7
2 100 50 12 22 15.6 ± 2.7
3 125 50 12 22 22.3 ± 3.4
4 150 50 12 22 28.7 ± 2.3
5 165 50 12 22 45.3 ± 2.9
6 180 50 12 22 33.3 ± 2.1
7 200 50 12 22 31.3 ± 4.8
8 250 50 12 22 28.9 ± 3.1
9 300 50 12 22 26.5 ± 1.9
Abbreviations: EE, entrapment efficacy; PVA, polyvinyl alcohol.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Table 2 results of drug loadings according to amount of surfactant (n = 3)
Formulation Polymer 
(mg)
PVA 
(mg)
Int. phase 
(mL)
Ext. phase 
(mL)
EE (%)
1 165 0 12 22 –
2 165 25 12 22 18.2 ± 5.8
3 165 35 12 22 23.4 ± 6.2
4 165 50 12 22 45.3 ± 2.9
5 165 75 12 22 28.8 ± 4.9
6 165 100 12 22 15.2 ± 4.2
Abbreviations: EE, entrapment efficacy; PVA, polyvinyl alcohol.
to be taken to the next phase of study like cytotoxicity and 
in vivo studies.
Preparation of nanoparticles
First formulations showed that drug amounts more than 
1 mg/mL had yellow sedimentation and loading efficiency 
was not increased by adding amounts of drug and supernatant, 
indicating that nanoparticles could not accept amounts more 
than 1 mg/mL.
Several formulations were prepared and four variables 
were considered, and the drug loadings were obtained to 
identify the best loading in order to select one optimum for-
mulation and to characterize the other physical assessments 
on the optimum one (Tables 1–4).
In comparing the results of calculated loadings, increasing 
the amount of polymer has a marked effect on drug loading 
(Table 1).
Amount of the emulsifier has no significant effect on 
encapsulation of drug but it is necessary for nanoparticle 
preparation (Table 2). The volume of internal phase and exter-
nal phase has a reversal effect on drug loading after volumes 
of 12 mL and 22 mL, respectively (Tables 3 and 4).
As the results show, the optimum formulation is the one 
consisting of 165 mg polymer, 50 mg PVA, 12 mL, and 
22 mL internal and external phases, respectively, which had 
a drug content of more than 45%.
The PLGA nanoparticle which is used as control group in 
comparison of physicochemical characteristics was achieved 
by 165.27 mg of polymer, 1.31% of emulsifier, 21.33 mL 
external phase, and 12 mL internal phase volumes. The 
resulting 9-NC PLGA nanoparticles showed the response 
to size with average of 207 nm and drug loading of about 
33%.7
Nanoparticle characterization
The morphology of the optimized PLGA-PEG nanoparticles 
examined by SEM was spherical as shown in Figure 4. 
Average size of nanoparticles was found to be around 
148.5 ± 30 nm with a polydispersity of 0.07%. It is 
concluded that the steric barrier of PEG shell could be 
the main cause to avoid aggregation of internal phase 
droplets in preparation pathway; therefore PLGA-PEG 
nanoparticles have a smaller size than PLGA ones. The 
zeta potential of the nanoparticles was about +1.84 mV 
over what is suitable for stable colloidal dispersion of 
nanoparticles.
The DSC thermograms of 9-NC, PLGA-PEG copolymer, 
physical mixture of drug and polymer, and 9-NC nanopar-
ticles are shown in Figure 5. The DSC curve of 9-NC showed 
a single melting peak which started to degrade as it melted. 
The PLGA-PEG thermogram displayed an endothermic peak 
investigative of polymer transition temperature (Tg). No 
9-NC melting peak was visible in the case of drug-loaded 
nanoparticles. This might be due to the amorphous state 
of the drug when dispersed in the nanoparticles. Since the 
curve of copolymer has not any shift in Tg, it is concluded 
that there is no occurrence of prominent interaction between 
the drug and copolymer.
Table 3 results of drug loadings according to internal phase volume (n = 3)
Formulation Polymer 
(mg)
PVA 
(mg)
Int. phase 
(mL)
Ext. phase 
(mL)
EE (%)
1 165 50 5 22 –
2 165 50 10 22 35.89 ± 4.2
3 165 50 12 22 45.3 ± 2.9
4 165 50 15 22 23.4 ± 4.7
5 165 50 25 22 11.7 ± 4.3International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 4 Dcs thermograms obtained for A) 9-Nc, B) Physical mixture, C) Nanoparticles, D) copolymer.
Table 4 results of drug loadings according to amount of external volume (n = 3)
Formulation Polymer 
(mg)
PVA 
(mg)
Int. phase 
(mL)
Ext. phase 
(mL)
EE (%)
1 165 0 12 5 –
2 165 25 12 10 10.1 ± 6.9
3 165 35 12 20 13.1 ± 5.2
4 165 50 12 22 45.3 ± 2.9
5 165 75 12 25 38.3 ± 7.4
6 165 100 12 30 30.0 ± 8.6
Regarding physical mixture, there is not any peak at the 
melting point of 9-NC. According to glass liquid transition 
of PLGA-PEG which is at lower temperatures, it is possible 
that at higher temperatures molecular dispersion of drug in 
polymer occurs during DSC process.
XRD patterns were used to confirm these results, 
and these are shown in Figure 5. As can be seen, the 
curves of 9-NC exhibit a sharp peak at about 2θ scat-
tered angle 27 indicating the crystalline nature of 9-NC. 
This kind of trait was absent in pattern of nanoparticles 
investigating that 9-NC was not in crystalline form in 
nanoparticles.
In vitro drug release
The 9-NC release profiles from optimum PLGA-PEG nano-
particles are shown in Figure 6. The procedure was performed 
using the dialysis technique using a dialysis membrane having 
a molecular weight cutoff of 12,000 Da (Sigma, St. Louis, MO) 
which was fixed on Franz diffusion cell and donor and accep-
tor medium was PBS (pH 7.4). In the release curve, two 
parts are seen. The first part shows the initial phase of release 
which has a rapid trend during the first 5 hours, followed by a 
distinct prolonged release for more than 120 hours. The rapid 
initial release can be due to a part of drug on the surface of 
nanoparticles and the delayed part is thought to be because of International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 5 XrD patterns. A) 9-Nc, B) copolymer, C) Nanoparticle, D) Physical mixture of drug and copolymer.
diffusion of dissolved drug through polymeric matrix and its 
exit to the dissolution medium, where as in our previous study 
about 20% of the drug was released over a period of 20 hours, 
followed by an extended release period of more than 160 hours 
(see Figure 6). This difference of release profile could be 
explained by presence of the hydrophilic PEG shell around 
the nanoparticles, causing increased diffusion of water to the 
core of particles. On the other hand, compared to plain PLGA 
nanoparticles, the hydrophilic surface decreases adsorption of 
lipophilic drugs on the surface of nanoparticles and decreases 
initial burst drug release.
Release kinetics was evaluated by calculating data via 
zero order, first order, and Higuchi equations. According to 
the results, the drug release followed the Higuchi equation 
and related correlation coefficients were better than both zero 
and first order kinetics (Table 5).
Two possible mechanisms according to the Higuchi 
model may be involved in the release of 9-NC from nanopar-
ticles; the dissolution diffusion of the drug from the matrices 
and matrix erosion resulting from degradation of polymer.
Baker and Lonsdale developed the equation: 2/3[1-(1-
Q)2/3]-Q = k.t, to describe the release of drug incorporated 
in a spherical matrix based on a diffusion mechanism.35 By 
fitting the observed data, shown in Figure 6, to the spherical 
matrix model, correlation coefficients of between 0.956 and 
0.994 were obtained.
The  Hixson–Crowell  cube  root  model, 
(100-Q.t)1/3 = 1001/3- KHC.t, where KHC is the Hixson–Crowell 
rate constant, describes the release from the systems, where 
it depends on the change in surface area and diameter of the 
particles with time and mainly applies in case of systems, 
which dissolve or erode over time.36 By fitting the release 
data to this model, correlation coefficients of 0.880–0.937 
were obtained.
These results indicate that the release of 9-NC from 
nanoparticles may be more consistent with a diffusion 
mechanism than a matrix erosion mechanism. In similar 
studies, Gao and coworkers prepared different block 
copolymer micelles of 9-NC, amphiphilic copolymers 
Table 5 Results of release kinetics according to zero order, first 
order, and higuchi equations
Ka
h 
μg/h0.5
Regression coefficient (R2)
Higuchi First order Zero order
4.351 0.989 0.922 0.896
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of methoxy poly(ethylene glycol)-b-poly(D,L-lactide), 
and copolymers derived from d,l-lactide, trimethylene 
carbonate, and methylated poly(ethylene glycol).37,38 
These micelles could significantly increase drug solubil-
ity; release of 9-NC was nearly zero order after the burst 
release, and the long hydrophobic chain length led to 
slower release rate about 50% over 60 hours, similar to 
results gained in our experiment.37,38
In general, in vitro release profiles shows that these 
nanoparticles have the capacity to successfully release 9-NC 
using a sustained rate.
Conclusion
In this investigation, PLGA-PEG nanoparticles loaded 
with 9-NC (a novel potent anticancer drug) were prepared 
by nanoprecipitation, and the physicochemical character-
istics included an investigation of their properties, such 
as drug loading, morphology, size, and thermal behavior 
were evaluated and compared with the results of our previ-
ous study, in which these NPs were prepared using PLGA 
polymer instead of PLGA-PEG copolymer. The images 
of SEM indicated the optimized NPs were spherical in 
shape without any aggregation or adhesion. More detailed 
studies showed that the particle size of NPs through using 
PLGA-PEG is smaller than PLGA samples. Drug loading 
was much higher than the previous study, and the initial 
release was slower. But as mentioned above the total release 
was faster than PLGA NPs, which can be explained by the 
hydrophilic characteristic of PLGA-PEG copolymer. This 
point causes a rapid release compared with PLGA that is a 
lipophil polymer and can keep the drug longer than PLGA-
PEG copolymer.
Overall physical evaluation comparison shows that 
PLGA-PEG nanoparticles can be a promising controlled 
release delivery system of lipophilic drugs like 9-NC spe-
cially in cancer therapies which need an acute and target 
treatment during therapeutically period.
However, the in vivo behavior of drug release, the speed 
of clearance, and final biodistribution of nanoparticles also 
need to be confirmed in future studies.
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